Literature DB >> 25134846

Thyroglobulin autoantibodies switch to immunoglobulin (Ig)G1 and IgG3 subclasses and preserve their restricted epitope pattern after 131I treatment for Graves' hyperthyroidism: the activity of autoimmune disease influences subclass distribution but not epitope pattern of autoantibodies.

F Latrofa1, D Ricci, L Montanelli, P Piaggi, B Mazzi, F Bianchi, F Brozzi, P Santini, E Fiore, M Marinò, M Tonacchera, P Vitti.   

Abstract

The subclass distribution of thyroglobulin autoantibodies (TgAb) is debated, whereas their epitope pattern is restricted. Radioidine ((131)I) treatment for Graves' disease (GD) induces a rise in TgAb levels, but it is unknown whether it modifies subclass distribution and epitope pattern of TgAb as well. We collected sera from GD patients before (131) I treatment and 3 and 6 months thereafter. We measured total TgAb, TgAb light chains and TgAb subclasses by enzyme-linked immunosorbent assay (ELISA) in 25 patients. We characterized the TgAb epitope pattern in 30 patients by inhibiting their binding to (125-) (I) Tg by a pool of four TgAb-Fab (recognizing Tg epitope regions A, B, C and D) and to Tg in ELISA by each TgAb-Fab. Total TgAb immunoglobulin (Ig)G rose significantly (P = 0.024). TgAb κ chains did not change (P = 0.052), whereas TgAb λ chains increased significantly (P = 0.001) and persistently. We observed a significant rise in IgG1 and IgG3 levels after (131)I (P = 0.008 and P = 0.006, respectively), while IgG2 and IgG4 levels did not change. The rise of IgG1 was persistent, that of IgG3 transient. The levels of inhibition of TgAb binding to Tg by the TgAb-Fab pool were comparable. A slight, non-significant reduction of the inhibition by the immune-dominant TgAb-Fab A was observed 3 and 6 months after (131)I. We conclude that (131)I treatment for GD increases the levels of the complement-activating IgG1 and IgG3 subclasses and does not influence significantly the epitope pattern of TgAb. In autoimmune thyroid disease subclass distribution of autoantibodies is dynamic in spite of a stable epitope pattern.
© 2014 British Society for Immunology.

Entities:  

Keywords:  B-cell epitopes; Graves’ disease; IgG subclasses; intramolecular epitope spreading; thyroglobulin autoantibodies

Mesh:

Substances:

Year:  2014        PMID: 25134846      PMCID: PMC4238871          DOI: 10.1111/cei.12438

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  49 in total

1.  Lymphocytic thyroiditis on histology correlates with serum thyroglobulin autoantibodies in patients with papillary thyroid carcinoma: impact on detection of serum thyroglobulin.

Authors:  Francesco Latrofa; Debora Ricci; Lucia Montanelli; Roberto Rocchi; Paolo Piaggi; Eleonora Sisti; Lucia Grasso; Fulvio Basolo; Clara Ugolini; Aldo Pinchera; Paolo Vitti
Journal:  J Clin Endocrinol Metab       Date:  2012-04-26       Impact factor: 5.958

Review 2.  Properties of mouse and human IgG receptors and their contribution to disease models.

Authors:  Pierre Bruhns
Journal:  Blood       Date:  2012-04-25       Impact factor: 22.113

3.  Effect of radioactive iodine therapy on cytokine production in Graves' disease: transient increases in interleukin-4 (IL-4), IL-6, IL-10, and tumor necrosis factor-alpha, with longer term increases in interferon-gamma production.

Authors:  B M Jones; C C Kwok; A W Kung
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

4.  Cutting edge: IL-21 is a switch factor for the production of IgG1 and IgG3 by human B cells.

Authors:  Jérôme Pène; Jean-François Gauchat; Sandrine Lécart; Elodie Drouet; Paul Guglielmi; Vera Boulay; Adriana Delwail; Don Foster; Jean-Claude Lecron; Hans Yssel
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

5.  Affinity-enrichment of thyrotropin receptor autoantibodies from Graves' patients and normal individuals provides insight into their properties and possible origin from natural antibodies.

Authors:  Francesco Latrofa; Gregorio D Chazenbalk; Pavel Pichurin; Chun-Rong Chen; Sandra M McLachlan; Basil Rapoport
Journal:  J Clin Endocrinol Metab       Date:  2004-09       Impact factor: 5.958

6.  Development of autoantibodies before the clinical onset of systemic lupus erythematosus.

Authors:  Melissa R Arbuckle; Micah T McClain; Mark V Rubertone; R Hal Scofield; Gregory J Dennis; Judith A James; John B Harley
Journal:  N Engl J Med       Date:  2003-10-16       Impact factor: 91.245

7.  Human monoclonal thyroglobulin autoantibodies: epitopes and immunoglobulin genes.

Authors:  Francesco Latrofa; Martin Phillips; Basil Rapoport; Sandra M McLachlan
Journal:  J Clin Endocrinol Metab       Date:  2004-10       Impact factor: 5.958

8.  Thyroglobulin-thyroperoxidase autoantibodies are polyreactive, not bispecific: analysis using human monoclonal autoantibodies.

Authors:  Francesco Latrofa; Pavel Pichurin; Jin Guo; Basil Rapoport; Sandra M McLachlan
Journal:  J Clin Endocrinol Metab       Date:  2003-01       Impact factor: 5.958

9.  Iodine contributes to thyroid autoimmunity in humans by unmasking a cryptic epitope on thyroglobulin.

Authors:  Francesco Latrofa; Emilio Fiore; Teresa Rago; Lucia Antonangeli; Lucia Montanelli; Debora Ricci; Maria Annateresa Provenzale; Maria Scutari; Monica Frigeri; Massimo Tonacchera; Paolo Vitti
Journal:  J Clin Endocrinol Metab       Date:  2013-09-24       Impact factor: 5.958

10.  Thyroglobulin autoantibodies in patients with papillary thyroid carcinoma: comparison of different assays and evaluation of causes of discrepancies.

Authors:  Francesco Latrofa; Debora Ricci; Lucia Montanelli; Roberto Rocchi; Paolo Piaggi; Eleonora Sisti; Lucia Grasso; Fulvio Basolo; Clara Ugolini; Aldo Pinchera; Paolo Vitti
Journal:  J Clin Endocrinol Metab       Date:  2012-09-04       Impact factor: 5.958

View more
  5 in total

1.  Serum immunoglobulin G4 levels and Graves' disease phenotype.

Authors:  Carmen Sorina Martin; Anca Elena Sirbu; Minodora Andreea Betivoiu; Suzana Florea; Carmen Gabriela Barbu; Simona Vasilica Fica
Journal:  Endocrine       Date:  2016-11-07       Impact factor: 3.633

2.  Glycosylation of Anti-Thyroglobulin IgG1 and IgG4 Subclasses in Thyroid Diseases.

Authors:  Yuan Li; Chenxu Zhao; Keli Zhao; Nan Yu; Yan Li; Yang Yu; Yang Zhang; Zhijing Song; Youyuan Huang; Guizhi Lu; Ying Gao; Junqing Zhang; Xiaohui Guo
Journal:  Eur Thyroid J       Date:  2020-08-27

Review 3.  Thyroid Autoantibodies Display both "Original Antigenic Sin" and Epitope Spreading.

Authors:  Sandra M McLachlan; Basil Rapoport
Journal:  Front Immunol       Date:  2017-12-20       Impact factor: 7.561

4.  Clinical efficacy of Yingliu mixture combined with metimazole for treating diffuse goitre with hyperthyroidism and its impact on related cytokines.

Authors:  Hua Yang; Yilei Cong; Tengfei Wu; Hong Tang; Muhao Ma; Juanhua Zeng; Wenya Zhang; Zhen Lian; Xinyu Yang
Journal:  Pharm Biol       Date:  2017-12       Impact factor: 3.503

5.  Serum thyroglobulin evaluation on LC-MS/MS and immunoassay in TgAb-positive patients with papillary thyroid carcinoma.

Authors:  Eijun Nishihara; Yoshitaka Hobo; Akira Miyauchi; Yasuhiro Ito; Miyoko Higuchi; Mitsuyoshi Hirokawa; Mitsuru Ito; Shuji Fukata; Mitsushige Nishikawa; Takashi Akamizu
Journal:  Eur Thyroid J       Date:  2022-01-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.